The Parkinson's Disease Therapeutics Conference is The Michael J. Fox Foundation's annual scientific conference and the only one in the world focused exclusively on Parkinson's disease drug development. The 13th Annual PD Therapeutics Conference will be held on October 15, 2019 at Convene Midtown East, New York City.
We are delighted to have Richard Hargreaves, PhD, Corporate VP, Neuroscience at Celgene chair our 2019 event.
The PD Therapeutics Conference brings together 300 research and business development professionals from both academia and industry and showcases the most exciting and innovative research from MJFF's research portfolio. Novel advances in basic and translational research from both academic and industry labs are highlighted through speaker presentations and a poster session. The event is a platform for field leaders to share new and unpublished results and for fostering new relationships and collaborations.
Registration for our 2019 conference is now open.
Convene Conference Center
730 Third Ave. (Between 45th and 46th Streets
New York, NY 10017
Please contact email@example.com.
Richard Hargreaves, PhD, is Corporate VP, Neuroscience at Celgene. Dr. Hargreaves previously held positions at Biogen and Merck and has decades of experience in the development of drug candidates and PET imaging agents for neuroscience indications.
Daniel Kacy Cullen, PhD
Research Associate Professor Of Neurosurgery, University of Pennsylvania School of Medicine
Tatiana Foroud, PhD
Chair, Department of Medical and Molecular Genetics, Indiana University
J. Timothy Greenamyre, MD, PhD
Professor of Neurology; Chief, Movement Disorders Division; Director, Pittsburgh Institute for Neurodegenerative Diseases (PIND) at the University of Pittsburgh
Ashley S. Harms, PhD
Assistant Professor, Department of Neurology, University of Alabama at Birmingham
Poul Henning Jensen, MD, PhD
Professor and Core Group Leader, The Danish Research Institute of Translational Neuroscience
Karl Kieburtz, MD, MPH
Robert J. Joynt Professor in Neurology, Senior Associate Dean for Clinical Research, Director of the Clinical & Translational Science Institute at the University of Rochester Medical Center
Kenneth Marek, MD
President and Senior Scientist at The Institute for Neurodegenerative Disorders
Miratul Muqit, MD, PhD
Professor, School of Life Sciences, University of Dundee
Sergio Pablo Sardi, PharmD, PhD
Research & Development Director, Neurobiology Unit, Sanofi Genzyme
Ira Shoulson, MD
Co-Founder and Principal, Grey Matter
Tanya Simuni, MD
Chief of Movement Disorders in the Department of Neurology; Arthur C. Nielsen, Jr., Research Professor of Parkinson's Disease and Movement Disorders; Professor of Neurology, Northwestern University
Jan Stoehr, PhD
Head of Non-Alzheimer's Disease Proteinopathies, AC Immune
Michael Schwarzschild, MD, PhD
Featured Poster: Results from the SURE-PD3 Trial
Roger Albin, MD
Alpha4Beta2 Nicotinic Agonist for Treatment of L-Dopa Refractory Gait and Balance Disorders in Parkinson's Disease
Rosa Canet-Aviles, PhD
AMP PD: Collaborating in the Discovery of Biomarkers to Accelerate the Development of Therapies for Parkinson's Disease
Matthew Havrda, PhD
Plasma-borne Pyroptosis-related Protein NLRP3 Associated with Parkinson’s Disease
Lorraine Iacovitti, PhD
Validating Astrocyte-Produced Protein GDF15 as a Novel Neuroprotective Therapy
Zachary Kabelac, PhD
Observational Study of Emerald Related to Mobility in Parkinson’s Patients
Heather Lasseter, PhD
RAPID-Dx Inflammatory Markers Platform Comparison Study
Sakura Minami, PhD
Targeting the Eotaxin/CCR3 Pathway in Mouse Models of Parkinson’s Disease
Inga Peter, PhD
Genetic, Clinical, and Therapeutic Links Between Crohn’s Disease and Parkinson’s Disease
Erik Stoops, PhD
Optimizing Standard Operating Procedures for Analysis of Alpha-Synuclein in Biological Fluids: A Data-Driven Approach
Marcus Unger, MD
The Effect of Resistant Starch on Bowel Habits, Short Chain Fatty Acids, and Gut Microbiota in Parkinson’s Disease - The RESISTA-PD Trial
Fei Wang, PhD
Identification of Comprehensive Progression PD Subtypes with PPMI
Convene at 730 Third Avenue is an incredible event space in Midtown East that is sure to impress your participants. One of our largest locations, it's perfect for your next town hall, conference, or reception and can seat up to 430 people in the Wharton Forum. The column-free, two-story room has 30 foot ceilings, with plenty of natural light and unobstructed and iconic views of Manhattan. As the first-ever Convene property and part of the company's signature collection, this property offers 40,000 square feet of space, with easy flow from the Forum space to 12 different breakout rooms which is ideal for multi-day events or trainings. Located just two blocks from Grand Central Terminal, 730 Third Avenue currently hosts the world's most important meetings and iconic events, from the James Beard Awards to attendees from the United Nations.
Sign up to receive all conference related updates in your inbox.